Kiniksa Pharmaceuticals International plc held its Annual Meeting of Shareholders on June 3, 2025. The re-election of Sanj K. Patel, Thomas R. Malley, and Richard S. Levy as Class I Directors was approved. The re-election of Stephen R. Biggar, G. Bradley Cole, and Barry was also approved. Additionally, the election of Felix J. Baker, M. Cantey Boyd, Tracey L. McCain, and Kimberly J. Popovits as Class III Directors was approved. The appointment of PricewaterhouseCoopers LLP as the company's UK statutory auditors and the ratification of PwC as the US independent registered public accounting firm for the fiscal year ending December 31, 2025, were both approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.